| 1 |
Garry GA, Garry DJ. Somatic cell therapy for chronic heart failure: in search of mechanistic insights[J]. J Card Fail, 2015,21(7):583-585.
|
| 2 |
Kamigaki T, Ibe H, Okada S, et al. Improvement of impaired immunological status of patients with various types of advanced cancers by autologous immune cell therapy[J]. Anticancer Res, 2015, 35(8):4535-4543.
|
| 3 |
Zhang B, Chen H. Quality management and outcome evaluation of cellular immunotherapy of cancer[J]. Chin J Cancer Biotherap, 2015, 22(1):8-15.
|
| 4 |
Mount NM, Ward SJ, Kefalas P, et al. Cell-based therapy technology classifications and translational challenges[J]. Philos Trans R Soc Lond B Biol Sci, 2015,370(1680):20150017.
|
| 5 |
Spohn G, Wiercinska E, Karpova D, et al. Automated CD34+ cell isolation of peripheral blood stem cell apheresis product[J]. Cytotherapy, 2015,17(10):1465-1471.
|
| 6 |
Huang W. Discussion on aseptic operation technique in sterile preparation[J]. Doctor, 2018(Z1):279-282.
|
| 7 |
Wang DL. The types safety and efficacity of the transplanted cells[J]. China Biotechnology, 2013,33(9):119-125.
|
| 8 |
Daley GQ, Insoo H, Apperley JF, et al. Setting global standards for stem cell research and clinical translation: the 2016 ISSCR guidelines[J]. Stem Cell Reports, 2016,6(6):787-797.
|
| 9 |
Lim JO. Regulation policy on cell- and tissue-based therapy products in Korea[J]. Tissue Eng Part A, 2015,21(23-24):2791-2796.
|
| 10 |
Setiawati A, Nguyen HT, Jung Y. Future research directions in the design of versatile extracellular matrix in tissue engineering[J]. Int Neurourol J, 2018,22(Suppl 2):S66-75.
|
| 11 |
韩立，惠利健，潘国字. 细胞的命运：间质干细胞的药代动力学[J]. 中国细胞生物学学报, 2018,40(6):857-866.
|
| 12 |
Cheng B, Lu SL, Fu XB. Regenerative medicine in China: main progress in different fields[J]. Mil Med Res, 2016, 3(1):24.
|
| 13 |
Tulina MA, Pyatigorskaya NV. Specificity of good manufacturing practice (GMP) for biomedical cell products[J]. Bull Exp Biol Med, 2018,164(4):579-582.
|
| 14 |
Bredenoord AL, Clevers H, Knoblich JA. Human tissues in a dish: the research and ethical implications of organoid technology[J]. Science, 2017,355(6322):eaaf9414.
|
| 15 |
Uphoff S, Lord ND, Okumus B, et al. Stochastic activation of a DNA damage response causes cell-to-cell mutation rate variation[J]. Science, 2016, 351(6277):1094-1097.
|
| 16 |
Goyal A, Murray JM. Modelling the impact of cell-to-cell transmission in hepatitis B virus[J]. Plos One, 2016,11(8):e0161978.
|
| 17 |
Solomon J, Csontos L, Clarke D, et al. Current perspectives on the use of ancillary materials for the manufacture of cellular therapies[J]. Cytotherapy, 2016,18(1):1-12.
|
| 18 |
Ji ST, Kim H, Yun J,et al. Promising therapeutic strategies for mesenchymal stem cell-based cardiovascular regeneration: from cell priming to tissue engineering[J]. Stem Cells Int, 2017,2017:3945403.
|
| 19 |
Kempf H, Andree B, Zweigerdt R. Large-scale production of human pluripotent stem cell derived cardiomyocytes[J]. Adv Drug Deliv Rev, 2016,96:18-30.
|
| 20 |
刘克斌. 理化实验室质量控制方法[J]. 中国城乡企业卫生, 2016,31(5):51-53.
|
| 21 |
Llobet L, Montoya J, Lópezgallardo E, et al. Side effects of culture media antibiotics on cell differentiation[J]. Tissue Eng Part C Methods, 2015,21(11):1143-1147.
|
| 22 |
Pamies D, Bal-Price A, Simeonov A, et al. Good cell culture practice for stem cells and stem-cell-derived models[J]. ALTEX, 2017, 34(1):95-132.
|
| 23 |
Atouf F. Cell-based therapies formulations: unintended components[J]. AAPS J, 2016,18(4):844-888.
|
| 24 |
Andrews PW, Ben-David U, Benvenisty N, et al. Assessing the safety of human pluripotent stem cells and their derivatives for clinical applications[J]. Stem Cell Reports, 2017,9(1):1-4.
|
| 25 |
Andrews PW, Baker D, Benvinisty N, et al. Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI)[J]. Regen Med, 2015,10(2 suppl):1-44.
|
| 26 |
中国医药生物技术协会. 干细胞制剂制备质量管理自律规范[J]. 中国医药生物技术, 2016,11(6):481-490.
|
| 27 |
Chen C, Cui ZR, Huang ZH. Control strategy for the production of trypsin for injection[J]. Shanghai Med Pharm J, 2018,39(13):87-91.
|
| 28 |
Kamigaki T, Matsuda E, Okada S, et al. Prospective evaluation of safety of immune-cell therapy for patients with various types of advanced cancer[J]. Anticancer Res, 2014,34(8):4601-4607.
|
| 29 |
Brown J, Kudrin A. Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health[J]. Biologicals, 2016,44(4):257-266.
|
| 30 |
中国医药生物技术协会. 免疫细胞制剂制备质量管理自律规范[J]. 中国医药生物技术, 2016,11(5):385-393.
|
| 31 |
萧惠来. FDA发布的"改变剂型和改变给药途径药品非临床安全性评价指导原则"介绍[J]. 药物评价研究, 2016,39(2):171-174.
|
| 32 |
Wong J, Jeraj H, Vilar E, et al. Endotoxin detection in end-stage kidney disease[J]. J Clin Pathol, 2015,68(1):73-78.
|
| 33 |
Food and Drug Administration, HHS. Revisions to exceptions applicable to certain human cells, tissues, and cellular and tissue-based products. Final rule[J]. Fed Regist, 2016,81(120):40512-40518.
|